🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

207 results for “Smith” Clear

  1. GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  2. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  3. GSK2118436

    GlaxoSmithKline

    Cancer

    phase 3 small molecule completed

    1 trial

  4. GSK2585823(CLDM 1%-BPO 3% gel)

    GlaxoSmithKline

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  5. GSK3196165 (Otilimab)

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 3 mab completed

    1 trial

  6. GW406381

    GlaxoSmithKline

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  7. GW685698/GW642444

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  8. Gepotidacin

    GlaxoSmithKline

    Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  9. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  10. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  11. H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  12. Hepatitis B adjuvanted vaccine

    GlaxoSmithKline

    Hepatitis B

    phase 3 mab completed

    1 trial

  13. Human rotavirus liquid vaccine

    GlaxoSmithKline

    Infections, Rotavirus

    phase 3 mab completed

    1 trial

  14. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. Infanrix hexa™

    GlaxoSmithKline

    Poliomyelitis

    phase 3 mab completed

    1 trial

  16. Infanrix-IPV+Hib™

    GlaxoSmithKline

    Acellular Pertussis

    phase 3 mab completed

    1 trial

  17. Influenza A (H5N1) Virus monovalent vaccine

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  18. Influenza vaccine GSK1562902A Formulation 1

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  19. Influenza vaccine GSK2321138A

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  20. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  21. Lapatinib

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule completed

    1 trial

  22. Locally sourced sterile 0.9% (w/v) sodium chloride, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  23. MEPOLIZUMAB

    GlaxoSmithKline

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  24. Mencevax ACWY

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources